Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NANOFER-THE-0504
- Development stage
- Unknown
- Lead developer
- Thena Biotech
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
NANOFER-THE-0504 is a targeted nanoparticle-based therapeutic developed by Thena Biotech for the treatment of solid tumors. It utilizes a human H-ferritin (HFn) nanocage as a delivery vehicle, which naturally targets the Transferrin Receptor 1 (TfR1/CD71) overexpressed on the surface of many cancer cells. The nanocage is loaded with doxorubicin, a cytotoxic anthracycline. This targeted delivery approach aims to increase the concentration of the drug within the tumor microenvironment while reducing systemic toxicity, particularly cardiotoxicity associated with free doxorubicin. The drug is currently being evaluated in Phase 1 clinical trials for patients with advanced solid tumors.
- Other names
- Nanofer-DoxNanoferritin-Doxorubicin
02
Targets
TOP1 (DNA Topoisomerase I)TFRC (Transferrin Receptor)DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on NANOFER-THE-0504.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NANOFER-THE-0504.